Tomohiro Oishi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tomohiro Oishi has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
- Takashi Nakano
Department of Pediatrics, Kawasaki Medical School, 577, Matsushima, Kurashiki 701-0192, Okayama, Japan
9 shared publications - Atsushi Kato
Department of Pediatrics, Kawasaki Medical School, Okayama, Japan
8 shared publications - Satoko Ogita
Department of Pediatrica, Kawasaki Medical School, Japan
6 shared publications Kazunobu Ouchi
Department of Pediatrics Kawasaki Medical School Kurashiki Japan
5 shared publications- Kazunobu Ouchi
Department of Pediatrics, Kawasaki Medical School, Okayama, Japan
5 shared publications - Daisuke Yoshioka
Department of Clinical Infectious Diseases, Kawasaki Medical School, 577 Matsushima, Kurashiki 701-0192, Japan
4 shared publications
Latest Publications
- Open Access
Evaluation of Respiratory Syncytial Virus Prefusion F IgG Antibodies in Japanese Mother–Infant Pairs Following Maternal Abrysvo Vaccination and in Infants Hospitalized with RSV Infection
Background/Objectives: The approval of Abrysvo, a maternal bivalent respiratory syncytial virus (RSV) prefusion F (pre-F) vaccine, marked a major milestone in pediatric prophylaxis. However, real-world serological data on transplacental antibody transfer in Asian populations remains limited. This brief report evaluated serum RSV pre-F immunoglobulin G (IgG) geometric mean titers (GMTs) across three distinct Japanese cohorts. Methods: This single-center, comparative study analyzed neonates born to Abrysvo-vaccinated mothers (n = 12), neonates born to unvaccinated mothers (n = 40), and infants aged n = 18) using enzyme-linked immunosorbent assay (ELISA). Results: Neonates of vaccinated mothers exhibited significantly higher pre-F IgG GMTs (4.74; 95% CI: 4.30–5.18) than those of unvaccinated mothers (3.80; 95% CI: 3.50–4.14). Conversely, infants requiring hospitalization for RSV infection demonstrated critically low pre-F IgG GMTs (1.08; 95% CI: 0.65–2.15), revealing statistically significant differences across all three groups (p < 0.001). Conclusions: Maternal immunization with Abrysvo significantly enhances passive humoral immunity in Japanese neonates compared to natural background immunity. Given the severe antibody deficiency observed in hospitalized infants, expanding maternal vaccination coverage is a high-priority public health strategy to mitigate the pediatric RSV burden in the post-pandemic era.
Open AccessEvaluation of Respiratory Syncytial Virus Prefusion F IgG Antibodies in Japanese Mother–Infant Pairs Following Maternal Abrysvo Vaccination and in Infants Hospitalized with RSV Infection
Background/Objectives: The approval of Abrysvo, a maternal bivalent respiratory syncytial virus (RSV) prefusion F (pre-F) vaccine, marked a major milestone in pediatric prophylaxis. However, real-world serological data on transplacental antibody transfer in Asian populations remains limited. This brief report evaluated serum RSV pre-F immunoglobulin G (IgG) geometric mean titers (GMTs) across three distinct Japanese cohorts. Methods: This single-center, comparative study analyzed neonates born to Abrysvo-vaccinated mothers (n = 12), neonates born to unvaccinated mothers (n = 40), and infants aged n = 18) using enzyme-linked immunosorbent assay (ELISA). Results: Neonates of vaccinated mothers exhibited significantly higher pre-F IgG GMTs (4.74; 95% CI: 4.30–5.18) than those of unvaccinated mothers (3.80; 95% CI: 3.50–4.14). Conversely, infants requiring hospitalization for RSV infection demonstrated critically low pre-F IgG GMTs (1.08; 95% CI: 0.65–2.15), revealing statistically significant differences across all three groups (p < 0.001). Conclusions: Maternal immunization with Abrysvo significantly enhances passive humoral immunity in Japanese neonates compared to natural background immunity. Given the severe antibody deficiency observed in hospitalized infants, expanding maternal vaccination coverage is a high-priority public health strategy to mitigate the pediatric RSV burden in the post-pandemic era.
- Open Access
- 1 September 2026
- Published by SAGE Publications in Sage Open Medicine
- Vol. 14
Antimicrobial susceptibility and clinical outcomes of tosufloxacin for mycoplasma pneumoniae among Japanese children in 2024
Background: Mycoplasma pneumoniae is a pathogen that causes community-acquired pneumonia. In 2024, for the first time since 2016, M. pneumoniae infections were epidemic in Japan. Recently, macrolide resistance has emerged among these pathogens. As tosufloxacin (TFLX) is the only antibiotic approved for use in children below the age of 8 years, this study investigated susceptibility and related clinical outcomes of TFLX treatment. Methods: This multi-center retrospective observational study evaluated 38 children with M. pneumoniae infections. Isolates were collected via nasopharyngeal culture, and TFLX minimum inhibitory concentrations (MICs) were determined. Detailed clinical courses were evaluated for patients treated with TFLX. Results: The TFLX minimum inhibitory concentration of their isolates ranged from 0.0625 to 0.5 g/mL, that TFLX MIC values remained within a low and favorable range Among seven patients who received TFLX against M. pneumoniae infections, five exhibited defervescence within 48 h of TFLX treatment onset, one was accompanied by COVID-19 infections, and one initiated TFLX on day 10 post-fever onset. Conclusion: In conclusion, TFLX is currently retains favorable microbiological susceptibility and suggested clinical usefulness.
- 1 September 2026
- Published by SAGE Publications in Sage Open Medicine
- Vol. 14
Open AccessAntimicrobial susceptibility and clinical outcomes of tosufloxacin for mycoplasma pneumoniae among Japanese children in 2024
Background: Mycoplasma pneumoniae is a pathogen that causes community-acquired pneumonia. In 2024, for the first time since 2016, M. pneumoniae infections were epidemic in Japan. Recently, macrolide resistance has emerged among these pathogens. As tosufloxacin (TFLX) is the only antibiotic approved for use in children below the age of 8 years, this study investigated susceptibility and related clinical outcomes of TFLX treatment. Methods: This multi-center retrospective observational study evaluated 38 children with M. pneumoniae infections. Isolates were collected via nasopharyngeal culture, and TFLX minimum inhibitory concentrations (MICs) were determined. Detailed clinical courses were evaluated for patients treated with TFLX. Results: The TFLX minimum inhibitory concentration of their isolates ranged from 0.0625 to 0.5 g/mL, that TFLX MIC values remained within a low and favorable range Among seven patients who received TFLX against M. pneumoniae infections, five exhibited defervescence within 48 h of TFLX treatment onset, one was accompanied by COVID-19 infections, and one initiated TFLX on day 10 post-fever onset. Conclusion: In conclusion, TFLX is currently retains favorable microbiological susceptibility and suggested clinical usefulness.
- Open Access
- 26 May 2026
- Published by Elsevier in The Lancet Microbe
- p. 101429
Improving prediction of future Mycoplasma pneumoniae epidemics using data-driven transmission models
- 26 May 2026
- Published by Elsevier in The Lancet Microbe
- p. 101429
Open AccessImproving prediction of future Mycoplasma pneumoniae epidemics using data-driven transmission models
- Open Access
- 13 January 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 167
Analysis of Macrolide Resistance in Bordetella pertussis Isolated from Japanese Children in 2025 Using Test Kit and Sequence Method
Background: Bordetella pertussis causes pertussis, a respiratory infection with whooping cough. Despite a high vaccine coverage, pertussis resurged post-COVID-19 pandemic. Meanwhile, isolates resistant to macrolides—the first-line therapy—have increased in several countries, including Japan. Culturing B. pertussis and detecting resistance are difficult; reports remain limited in Japan. Methods: From March to August 2025, we collected nasopharyngeal samples from children aged 0–15 years with suspected pertussis at six Japanese clinics. Pediatricians obtained swabs and tested them using gene-amplification kits (e.g., BioFire® SpotFire® in four clinics, LAMP Pertussis Detection® in two clinics). B. pertussis was confirmed by PCR; isolates were sequenced to identify macrolide-resistant mutations. Results: Samples were taken from 54 children, the number of boys and girls was 34 and 20, and their median age was 12 years old. Among 54 B. pertussis isolates, 43/52 (82.7%) sequenced strains harbored the A2047G mutation associated with macrolide resistance. Resistance rates at each clinic varied from 40% to 96%. Conclusions: These findings indicate a post-pandemic rise in macrolide-resistant B. pertussis in Japan. Ongoing resistance surveillance is essential, and repurposing residual clinical samples after routine testing is useful given culture and detection challenges.
- 13 January 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (1) , 167
Open AccessAnalysis of Macrolide Resistance in Bordetella pertussis Isolated from Japanese Children in 2025 Using Test Kit and Sequence Method
Background: Bordetella pertussis causes pertussis, a respiratory infection with whooping cough. Despite a high vaccine coverage, pertussis resurged post-COVID-19 pandemic. Meanwhile, isolates resistant to macrolides—the first-line therapy—have increased in several countries, including Japan. Culturing B. pertussis and detecting resistance are difficult; reports remain limited in Japan. Methods: From March to August 2025, we collected nasopharyngeal samples from children aged 0–15 years with suspected pertussis at six Japanese clinics. Pediatricians obtained swabs and tested them using gene-amplification kits (e.g., BioFire® SpotFire® in four clinics, LAMP Pertussis Detection® in two clinics). B. pertussis was confirmed by PCR; isolates were sequenced to identify macrolide-resistant mutations. Results: Samples were taken from 54 children, the number of boys and girls was 34 and 20, and their median age was 12 years old. Among 54 B. pertussis isolates, 43/52 (82.7%) sequenced strains harbored the A2047G mutation associated with macrolide resistance. Resistance rates at each clinic varied from 40% to 96%. Conclusions: These findings indicate a post-pandemic rise in macrolide-resistant B. pertussis in Japan. Ongoing resistance surveillance is essential, and repurposing residual clinical samples after routine testing is useful given culture and detection challenges.
- Open Access
- 25 September 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (10) , 2243
Macrolide-Resistant Mycoplasma pneumoniae Among Japanese Children from 2008 to 2024
Mycoplasma pneumoniae (MP), an important pathogen that causes pneumonia among children and young adults, caused an epidemic every four years in Japan until 2016, with the next epidemic occurring eight years later in 2024. This study compared the prevalence of MP infections among Japanese children in 2024 to previous years using real-time polymerase chain reaction (PCR) and the p1 genotype determined using the PCR restriction fragment length polymorphism typing method from nasopharyngeal swab specimens. Of the 133 total isolates collected in 2024, 54.1% were macrolide-resistant MP (MRMP), with 98.0% of those containing an A2063G mutation in the 23S rRNA gene associated with macrolide resistance. This annual rate of MRMP and incidence of the A2063G mutation was similar to those in 2016. However, the dominant p1 genotype among isolates in 2024 was type 1 (93.4%), whereas type 2 was dominant in the previous epidemic. Thus, although the rate of MRMP in 2024 was similar to that in the previous epidemic year, the distribution of p1 genotypes was different. Further, the rate of MRMP was lower than neighboring Asian countries, including China and Korea, but was higher than in European countries. Therefore, it is important to continue monitoring MP infections in Japan.
- 25 September 2025
- Published by MDPI AG in Microorganisms
- Vol. 13 (10) , 2243
Open AccessMacrolide-Resistant Mycoplasma pneumoniae Among Japanese Children from 2008 to 2024
Mycoplasma pneumoniae (MP), an important pathogen that causes pneumonia among children and young adults, caused an epidemic every four years in Japan until 2016, with the next epidemic occurring eight years later in 2024. This study compared the prevalence of MP infections among Japanese children in 2024 to previous years using real-time polymerase chain reaction (PCR) and the p1 genotype determined using the PCR restriction fragment length polymorphism typing method from nasopharyngeal swab specimens. Of the 133 total isolates collected in 2024, 54.1% were macrolide-resistant MP (MRMP), with 98.0% of those containing an A2063G mutation in the 23S rRNA gene associated with macrolide resistance. This annual rate of MRMP and incidence of the A2063G mutation was similar to those in 2016. However, the dominant p1 genotype among isolates in 2024 was type 1 (93.4%), whereas type 2 was dominant in the previous epidemic. Thus, although the rate of MRMP in 2024 was similar to that in the previous epidemic year, the distribution of p1 genotypes was different. Further, the rate of MRMP was lower than neighboring Asian countries, including China and Korea, but was higher than in European countries. Therefore, it is important to continue monitoring MP infections in Japan.
- Open Access
- 17 March 2025
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 11 (1) , 1-6
Efficacy of baloxavir marboxil as a prophylactic against influenza among in-patients and analysis of influenza virus mutations in their isolates at a Japanese hospital during the 2023–2024 flu season
Background: Baloxavir marboxil (baloxavir) is a new anti-influenza drug that works as a cap-dependent endonuclease inhibitor. It is approved for prophylactic use against influenza in Japan, but there are few reports on this usage in hospitalized in-patients. It reportedly reduces patient susceptibility to influenza through a mechanism involving amino acid substitution. Methods: Between August 2023 and July 2024, we investigated the efficacy of baloxavir as a prophylactic against influenza among in-patients at our hospital who had close contact with patients who were infected with influenza viruses in the same rooms. We also investigated the I38T influenza virus variant to baloxavir through samples taken from patients with the virus at the hospital. Results: We enrolled a total of 45 in-patients who had close contact with other patients who were confirmed to be infected with influenza in the same room. Among 34 of them who were prescribed baloxavir prophylactically, none developed influenza within 5 days from their last contact with infected patients. Conversely, among the other 11 who did not use baloxavir, three became infected with influenza within 5 days following contact with the infected patient (P = 0.012). In 85 samples taken from the patients with influenza, 25 were H1N1 types and 60 were H3N2. We detected the I38T variant of the cap-dependent endonuclease-baloxavir complex structure in two of the H3N2-type samples. Both of these patients had contracted influenza from their children. Conclusions: According to our results, Baloxavir represents an effective prophylactic against influenza for hospitalized in-patients. However, patients with genetic mutations related to decreased susceptibility to influenza, such as I38T variant, should nevertheless exercise higher levels of caution—particularly around children.
- 17 March 2025
- Published by Springer Nature in Journal of Pharmaceutical Health Care and Sciences
- Vol. 11 (1) , 1-6
Open AccessEfficacy of baloxavir marboxil as a prophylactic against influenza among in-patients and analysis of influenza virus mutations in their isolates at a Japanese hospital during the 2023–2024 flu season
Background: Baloxavir marboxil (baloxavir) is a new anti-influenza drug that works as a cap-dependent endonuclease inhibitor. It is approved for prophylactic use against influenza in Japan, but there are few reports on this usage in hospitalized in-patients. It reportedly reduces patient susceptibility to influenza through a mechanism involving amino acid substitution. Methods: Between August 2023 and July 2024, we investigated the efficacy of baloxavir as a prophylactic against influenza among in-patients at our hospital who had close contact with patients who were infected with influenza viruses in the same rooms. We also investigated the I38T influenza virus variant to baloxavir through samples taken from patients with the virus at the hospital. Results: We enrolled a total of 45 in-patients who had close contact with other patients who were confirmed to be infected with influenza in the same room. Among 34 of them who were prescribed baloxavir prophylactically, none developed influenza within 5 days from their last contact with infected patients. Conversely, among the other 11 who did not use baloxavir, three became infected with influenza within 5 days following contact with the infected patient (P = 0.012). In 85 samples taken from the patients with influenza, 25 were H1N1 types and 60 were H3N2. We detected the I38T variant of the cap-dependent endonuclease-baloxavir complex structure in two of the H3N2-type samples. Both of these patients had contracted influenza from their children. Conclusions: According to our results, Baloxavir represents an effective prophylactic against influenza for hospitalized in-patients. However, patients with genetic mutations related to decreased susceptibility to influenza, such as I38T variant, should nevertheless exercise higher levels of caution—particularly around children.
- Open Access
- 12 December 2024
- Published by MDPI AG in Preprints.org
Evaluation of Virus Detection in Pediatric Patients Hospitalized with Respiratory Tract Infections Using Quantitative Multiplex PCR
Respiratory tract infections (RTIs) are common in children. Viruses are known to be related to most pediatric infections. However, some pediatric cases of RTI have been found to be associated with multiple viruses. In this study, we collected samples from the nasopharynx of all pediatric patients admitted to our hospital with RTI between April 2022 and March 2023 and performed multiple quantitative real-time PCRs. Out of 77 patients involved, 67 (87.0%) tested positive for some or the other virus. Rhinovirus was the most detected, followed by the RS virus and parainfluenza virus type 3. Among the patients, 18 (26.9%) had multiple viral infections and 14 had complications associated with obstructive respiratory diseases, including bronchial asthma, acute bronchiolitis, and asthmatic bronchitis. Furthermore, some cases were found to have both the main and non-main viruses. Multiple viruses were detected in approximately one-fourth of the children with RTIs; complications associated with obstructive respiratory diseases were considered to be the main factors.
- 12 December 2024
- Published by MDPI AG in Preprints.org
Open AccessEvaluation of Virus Detection in Pediatric Patients Hospitalized with Respiratory Tract Infections Using Quantitative Multiplex PCR
Respiratory tract infections (RTIs) are common in children. Viruses are known to be related to most pediatric infections. However, some pediatric cases of RTI have been found to be associated with multiple viruses. In this study, we collected samples from the nasopharynx of all pediatric patients admitted to our hospital with RTI between April 2022 and March 2023 and performed multiple quantitative real-time PCRs. Out of 77 patients involved, 67 (87.0%) tested positive for some or the other virus. Rhinovirus was the most detected, followed by the RS virus and parainfluenza virus type 3. Among the patients, 18 (26.9%) had multiple viral infections and 14 had complications associated with obstructive respiratory diseases, including bronchial asthma, acute bronchiolitis, and asthmatic bronchitis. Furthermore, some cases were found to have both the main and non-main viruses. Multiple viruses were detected in approximately one-fourth of the children with RTIs; complications associated with obstructive respiratory diseases were considered to be the main factors.
- Open Access
- 30 October 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (11) , 1022
Impact of Education on Inappropriate Antibiotic Prescription for Respiratory Tract Infection Based on Physicians’ Justifications: A Web-Based Survey in Japan
Background: Antibiotics are inappropriately prescribed for respiratory tract infections for various reasons. The differences of the effects of education based on these reasons has not been fully elucidated. This study assessed the impact of an educational film on antibiotic prescription patterns according to physicians’ prescribing justifications. Methods: This was a secondary analysis of a nationwide web-based survey involving 1100 physicians. The physicians were required to view a short educational film and determine the need for prescribing antibiotics in simulated scenarios of different acute respiratory tract infectious diseases. The associations between the reasons for antibiotic prescription to patients not requiring antibiotics before viewing the educational film and the positive effects of the intervention were analyzed. Results: The educational intervention positively affected prescribing trends among physicians who prescribed antibiotics for “fever” in mild acute rhinosinusitis (prescription rates from 100% to 25.9%), “pus in the laryngopharynx” in mild acute pharyngitis (prescription rates from 100% to 29.6%), and “purulent sputum” in acute bronchitis without chronic lung disease (prescription rates from 100% to 29.9%) before viewing the film. In contrast, no benefits were observed when the justification was “patient’s desire for antibiotics” in mild acute pharyngitis (prescription rates from 100% to 48.5%) and acute bronchitis without chronic lung disease (prescription rates from 100% to 44.0%) or “parents’ desire for antibiotics” in narrowly defined common cold in children (prescription rates from 100% to 45.7%). Conclusions: although educational interventions might reduce inappropriate antibiotic prescription by providing accurate knowledge about respiratory tract infections, they appear ineffective for physicians who prescribe antibiotics based on patients’ or parents’ desires for antibiotic treatment.
- 30 October 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (11) , 1022
Open AccessImpact of Education on Inappropriate Antibiotic Prescription for Respiratory Tract Infection Based on Physicians’ Justifications: A Web-Based Survey in Japan
Background: Antibiotics are inappropriately prescribed for respiratory tract infections for various reasons. The differences of the effects of education based on these reasons has not been fully elucidated. This study assessed the impact of an educational film on antibiotic prescription patterns according to physicians’ prescribing justifications. Methods: This was a secondary analysis of a nationwide web-based survey involving 1100 physicians. The physicians were required to view a short educational film and determine the need for prescribing antibiotics in simulated scenarios of different acute respiratory tract infectious diseases. The associations between the reasons for antibiotic prescription to patients not requiring antibiotics before viewing the educational film and the positive effects of the intervention were analyzed. Results: The educational intervention positively affected prescribing trends among physicians who prescribed antibiotics for “fever” in mild acute rhinosinusitis (prescription rates from 100% to 25.9%), “pus in the laryngopharynx” in mild acute pharyngitis (prescription rates from 100% to 29.6%), and “purulent sputum” in acute bronchitis without chronic lung disease (prescription rates from 100% to 29.9%) before viewing the film. In contrast, no benefits were observed when the justification was “patient’s desire for antibiotics” in mild acute pharyngitis (prescription rates from 100% to 48.5%) and acute bronchitis without chronic lung disease (prescription rates from 100% to 44.0%) or “parents’ desire for antibiotics” in narrowly defined common cold in children (prescription rates from 100% to 45.7%). Conclusions: although educational interventions might reduce inappropriate antibiotic prescription by providing accurate knowledge about respiratory tract infections, they appear ineffective for physicians who prescribe antibiotics based on patients’ or parents’ desires for antibiotic treatment.
- Open Access
- 11 September 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (1) , 6-10
Maximum Diameter of Ileocecal Lymph Nodes Measured Using Abdominal Ultrasonography Allows for the Discrimination of Yersinia pseudotuberculosis Infection from Kawasaki Disease
Background: This study aimed to determine whether the maximum diameter of ileocecal lymph nodes measured using abdominal ultrasonography is useful for differentiating Yersinia pseudotuberculosis infection from Kawasaki disease in the acute phase. The optimal maximum diameter cutoff of the ileocecal lymph nodes was also explored to optimize differentiation between these 2 diseases. Methods: We included pediatric patients Y. pseudotuberculosis infection. Results: Of the 122 patients included in the analysis, 17 were confirmed to have Y. pseudotuberculosis infection and 105 were not. The age (in months), white blood cell count, C-reactive protein level, prediction score (risk score) for nonresponse to intravenous immunoglobulin, and number of intravenous immunoglobulin doses did not differ significantly between the Y. pseudotuberculosis-positive and -negative groups. The maximum diameter of ileocecal lymph nodes was 6.0 (5.5–9.5) mm in the Y. pseudotuberculosis-positive group and 3.0 (2.5–3.8) mm in the Y. pseudotuberculosis-negative group (numbers presented as median, interquartile range), with a significantly larger diameter in the Y. pseudotuberculosis-positive group (P < 0.01, Mann–Whitney U test), suggesting potency of ultrasonography. Conclusion: In patients meeting the diagnostic criteria for Kawasaki disease, the possibility of Y. pseudotuberculosis infection is significantly higher if the maximum ileocecal lymph node diameter ≥5.1 mm. Its sensitivity and specificity being 100%, and 89.5%, respectively.
- 11 September 2024
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 44 (1) , 6-10
Open AccessMaximum Diameter of Ileocecal Lymph Nodes Measured Using Abdominal Ultrasonography Allows for the Discrimination of Yersinia pseudotuberculosis Infection from Kawasaki Disease
Background: This study aimed to determine whether the maximum diameter of ileocecal lymph nodes measured using abdominal ultrasonography is useful for differentiating Yersinia pseudotuberculosis infection from Kawasaki disease in the acute phase. The optimal maximum diameter cutoff of the ileocecal lymph nodes was also explored to optimize differentiation between these 2 diseases. Methods: We included pediatric patients Y. pseudotuberculosis infection. Results: Of the 122 patients included in the analysis, 17 were confirmed to have Y. pseudotuberculosis infection and 105 were not. The age (in months), white blood cell count, C-reactive protein level, prediction score (risk score) for nonresponse to intravenous immunoglobulin, and number of intravenous immunoglobulin doses did not differ significantly between the Y. pseudotuberculosis-positive and -negative groups. The maximum diameter of ileocecal lymph nodes was 6.0 (5.5–9.5) mm in the Y. pseudotuberculosis-positive group and 3.0 (2.5–3.8) mm in the Y. pseudotuberculosis-negative group (numbers presented as median, interquartile range), with a significantly larger diameter in the Y. pseudotuberculosis-positive group (P < 0.01, Mann–Whitney U test), suggesting potency of ultrasonography. Conclusion: In patients meeting the diagnostic criteria for Kawasaki disease, the possibility of Y. pseudotuberculosis infection is significantly higher if the maximum ileocecal lymph node diameter ≥5.1 mm. Its sensitivity and specificity being 100%, and 89.5%, respectively.
- Open Access
- 1 August 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (8) , 724
Impact of Educational Films on Antibiotic Prescription among Physicians: A Web-Based Survey in Japan
Although antibiotics are most frequently prescribed for respiratory tract infections, effective interventions for their proper use by physicians have not been fully established. We assessed the impact of educational films on the rates of antibiotic prescriptions for respiratory tract infections using fictitious scenarios. In this nationwide web-based survey prospective study, a total of 1100 physicians were included. The physicians were required to view educational short films and determine the need for prescribing antibiotics in 10 fictitious scenarios involving adults diagnosed with different acute respiratory tract infectious diseases. The antibiotic prescription rates for each scenario were compared before and after viewing the educational short film. The rates of antibiotic prescription significantly decreased after viewing the educational film, especially in cases with a narrowly defined common cold (from 51% to 15%), mild pharyngolaryngitis (from 71% to 25%), and acute bronchitis without chronic respiratory underlying diseases (from 63% to 23%). Alternatively, a slight decrease in rates was observed in cases with moderate or severe rhinosinusitis (from 94% to 79%), moderate or severe acute pharyngitis (from 88% to 69%), and acute bronchitis with chronic lung disease (from 70% to 58%), for which antibiotics are recommended. Educational short films may encourage the proper use of antibiotics for respiratory tract infections; however, the possibility of undertreatment in patients requiring antibiotics must be considered.
- 1 August 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (8) , 724
Open AccessImpact of Educational Films on Antibiotic Prescription among Physicians: A Web-Based Survey in Japan
Although antibiotics are most frequently prescribed for respiratory tract infections, effective interventions for their proper use by physicians have not been fully established. We assessed the impact of educational films on the rates of antibiotic prescriptions for respiratory tract infections using fictitious scenarios. In this nationwide web-based survey prospective study, a total of 1100 physicians were included. The physicians were required to view educational short films and determine the need for prescribing antibiotics in 10 fictitious scenarios involving adults diagnosed with different acute respiratory tract infectious diseases. The antibiotic prescription rates for each scenario were compared before and after viewing the educational short film. The rates of antibiotic prescription significantly decreased after viewing the educational film, especially in cases with a narrowly defined common cold (from 51% to 15%), mild pharyngolaryngitis (from 71% to 25%), and acute bronchitis without chronic respiratory underlying diseases (from 63% to 23%). Alternatively, a slight decrease in rates was observed in cases with moderate or severe rhinosinusitis (from 94% to 79%), moderate or severe acute pharyngitis (from 88% to 69%), and acute bronchitis with chronic lung disease (from 70% to 58%), for which antibiotics are recommended. Educational short films may encourage the proper use of antibiotics for respiratory tract infections; however, the possibility of undertreatment in patients requiring antibiotics must be considered.